Cytokinetics CYTK Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -695.4%+2,207pp | -2,902.7%+3,687pp | -6,589.7%-6,247pp | -342.8%-78.2pp | |
| Net margin | -891.6%+2,300pp | -3,191.1%+3,798pp | -6,988.6%-6,577pp | -411.2%-105pp | |
| Efficiency | |||||
| Asset turnover | 0.1×0.0× | 0×0.0× | 0×-0.1× | 0.1×0.0× | |
| Liquidity | |||||
| Current ratio | 4.5×-1.6× | 6.2×0.0× | 6.1×-3.3× | 9.4×+1.9× | |
| Per Share | |||||
| Book value per share | -$5.49-354% | -$1.21+69.8% | -$4.00-233% | -$1.20-138% | |
| Valuation | |||||
| Market capitalization | $7.77B+39.9% | $5.55B-32.2% | $8.19B+88.8% | $4.34B+12.7% | |
| Price / sales | 88.2×-212× | 300.5×-787× | 1,087.2×+1,041× | 45.8×-8.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Cytokinetics's ratios come from?
- Every ratio is computed from Cytokinetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
